Skip to content
SNWV

SANUWAVE Health, Inc.

SANUWAVE Health, Inc. Q1 FY2025 earnings call

May 9, 2025 · fiscal period ended 2025-03

EPS · actual vs est

$-0.66 /

Revenue · actual vs est

$9.3M /
Ask about this call

Summary

Generated 2025-05-09

Management highlights

  • Q1 was a strong start with 61% year-on-year growth. Hired new head of sales and worked through Salesforce restructuring. Placed 98 systems, no unusually large orders, and no customer > mid-six percent of revenue. Ended quarter with 1,145 systems in the field, 429 placed in trailing twelve months. - Applicator sales up from Q1 2024, typical pattern with patients delaying treatment in Q1 due to out-of-pocket max reset. - Built up inventory on Ultramist systems and components, stockpiled long lead time components. - Uplist to Nasdaq had a $295,000 listing fee affecting operating profit, EBITDA, and adjusted EBITDA.
View in transcript ↓

Segment performance

For SANUWAVE Health, Inc., in the first quarter of 2025: Systems - Placed 98 new Altamist systems in Q1, a 28% increase from 43 in Q1 2024. Applicators - Sales in Q1 were $5.8 million vs $4.1 million in Q1 2024; applicators constituted 62% of revenues in Q1, within the 55-65% target.

View in transcript ↓

Guidance

  • Guiding to $10 million to $10.7 million in Q2 revenues, 40% to 50% year-on-year growth. - Annual guidance for 2025 remains 47% to 53% as on Q4 call.
View in transcript ↓

Risks

  • Forward-looking statements involve risks and uncertainties beyond company's control. - Economic and trade conditions could affect financial results. - Current tariff situation may impact cost availability or margins, but production is domestic and benefits from economies of scale.
View in transcript ↓

Q&A highlights

Q: Can you quantify system placements from smaller and larger customers?

A: It's complicated as grouping large customer groups is tricky; some customers grow rapidly, and time frames for sales vary from a couple days to several months.

Q: Address debt landscape and upcoming conferences?

A: Looking at refi opportunities for debt, no definitive plans yet for conferences but will keep posted.

Q: Market opportunity success segments and patent assertion?

A: No visibility into specific wound types treated; with patent assertion, working with a partner, but specifics are private and out of control.

Q: Insight into evolving sales strategy with new team member?

A: Pursuing engagement with larger customers, focusing on nursing homes, mobile/home health care, doctor's offices, and hospitals, with new sales executive bringing different experience.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$-0.66
Revenue$9.3M

Transcript

May 9, 2025

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.